Current Status of Generic Trastuzumab Emtansine
No generics for trastuzumab emtansine (Kadcyla) have entered the U.S. market. The drug, approved in 2013 for HER2-positive breast cancer, remains protected by multiple patents listed in the FDA's Orange Book, blocking FDA approval of abbreviated biologics (aBLA) until resolutions occur.[1] As of October 2024, no generic or biosimilar has launched commercially.
Key Patents Blocking Entry
Genentech (Roche) holds patents covering the antibody-drug conjugate structure, linker technology, and manufacturing processes, expiring between 2027 and 2034. The latest key patent (U.S. Patent 10,808,039) expires March 23, 2034.[2] DrugPatentWatch tracks 24 Orange Book patents, with the earliest expiry in 2027 for a formulation patent.[3]
Ongoing Litigation and Challenges
Sandoz and others filed biosimilar applications (eBLA) challenging patents via FDA's litigation pathway. Genentech sued Sandoz in 2023 over its trastuzumab emtansine biosimilar, with cases pending in California federal court.[4] Similar disputes delayed Kadcyla generics, mirroring Keytruda patent battles. No settlement announcements indicate imminent market entry.
When Could Biosimilars Launch?
Biosimilars need FDA approval plus patent settlements or wins. Earliest realistic U.S. entry is post-2027 if early patents lapse without injunctions, but core composition patents extend to 2034. Europe saw no biosimilars by mid-2024; EMA approvals lag due to complexity of the emtansine payload.[5] Roche's exclusivity ended in 2020, but patents dominate.
Alternatives Already Available
Physicians use generics of trastuzumab (Herceptin) alone or with chemotherapy, or competitors like Enhertu (trastuzumab deruxtecan), which has patent expiry in 2030 but faces its own challenges.[6] Phesgo (subcutaneous trastuzumab) has biosimilars in development.
[1]: FDA Orange Book: https://www.accessdata.fda.gov/scripts/cder/ob/
[2]: USPTO Patent Full-Text Database: https://patft.uspto.gov/
[3]: DrugPatentWatch.com: https://www.drugpatentwatch.com/p/trademark/KADCYLA
[4]: PACER court docket (Genentech v. Sandoz, N.D. Cal. 2023)
[5]: EMA Medicines: https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla
[6]: FDA Approvals: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-enhertu-her2-positive-unresectable-or-metastatic-breast